Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials

Authors :: Kenneth B Gordon
Richard G Langley
Richard B Warren
Yukari Okubo
David Rosmarin
Mark Lebwohl
Luke Peterson
Cynthia Madden
Dirk De Cuyper
Natalie Nunez Gomez
Diamant Thaçi
Source :: SKIN The Journal of Cutaneous Medicine. 6:s66
Publication Year :: 2022
Publisher :: National Society for Cutaneous Medicine, 2022.
Abstract: N/A

Tools